Srilatha Tangada Selected Research

BAX 855

7/2020	Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A.
9/2019	Perioperative haemostasis with full-length, PEGylated, recombinant factor VIII with extended half-life (rurioctocog alfa pegol) in patients with haemophilia A: Final results of a multicentre, single-arm phase III trial.
9/2019	Subgroup analysis of a phase 2/3 study of rurioctocog alfa pegol in patients with severe hemophilia A: efficacy and safety in previously treated Korean patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Srilatha Tangada Research Topics

Disease

6	Hemophilia A (Haemophilia) 05/2021 - 09/2019
4	Hemorrhage 07/2020 - 09/2019
2	Hemophilia B (Haemophilia B) 01/2020 - 01/2020
1	Procedural Pain 01/2020
1	Headache (Headaches) 09/2019

Drug/Important Bio-Agent (IBA)

5	Factor VIII (Coagulation Factor VIII)IBA 05/2021 - 09/2019
3	BAX 855IBA 07/2020 - 09/2019
3	Hemostatics (Antihemorrhagics)IBA 01/2020 - 09/2019
2	Factor IX (Coagulation Factor IX)FDA LinkGeneric 01/2020 - 01/2020
2	6-pyruvoyltetrahydropterin synthase (PTPS)IBA 01/2020 - 09/2019
1	Pharmaceutical PreparationsIBA 01/2020
1	gamma-AIBA 01/2020
1	prothrombin complex concentrates (PPSB)IBA 01/2020

Therapy/Procedure

1	Therapeutics 05/2021